Sanjay Kaul

Publication Activity (10 Years)

Years Active: 2017-2022
Publications (10 Years): 7

Top Topics

Psychometric Properties

Ejection Fraction

Cardiovascular Disease

Top Venues

This page only lists publications with an associated author ORCID identifier.

Publications

Sanjay Kaul
Pursuit of Myocardial Ischemia for Therapeutic Decision-Making in Patients With Diabetes and Stable Ischemic Heart Disease: Reconciling Randomized Controlled Trials and Observational Studies. Diabetes care 45 (12) (2022)
Matthew C Riddle, null null, George L Bakris, Lawrence Blonde, Andrew J M Boulton, Jessica R Castle, Linda A DiMeglio, Linda Gonder-Frederick, Frank B Hu, Steven E Kahn, Sanjay Kaul, Robert Geoffrey Moses, Stephen S Rich, Julio Rosenstock, Elizabeth Selvin, Adrian Vella, Judith Wylie-Rosett
Editorial Cycles and Continuity of Diabetes Care. Diabetes care 45 (7) (2022)
Javed Butler, Gerasimos S Filippatos, Tariq Jamal Siddiqi, Joao Pedro Ferreira, Martina Brueckmann, Edimar Alcides Bocchi, Michael Böhm, Vijay K Chopra, Nadia Giannetti, Tomoko Iwata, James L Januzzi, Sanjay Kaul, Iliana L Piña, Piotr Ponikowski, Ursula Rauch, Sanjiv J Shah, Michele Senni, Mikhail Sumin, Subodh Verma, Jian Zhang, Stuart J Pocock, Faiez Zannad, Milton Packer, Stefan D Anker
Effects of Empagliflozin in Women and Men With Heart Failure and Preserved Ejection Fraction. Circulation 146 (14) (2022)
Javed Butler, Gerasimos S Filippatos, Tariq Jamal Siddiqi, Martina Brueckmann, Michael Böhm, Vijay K Chopra, Joao Pedro Ferreira, James L Januzzi, Sanjay Kaul, Iliana L Piña, Piotr Ponikowski, Sanjiv J Shah, Michele Senni, Ola Vedin, Subodh Verma, Barbara Peil, Stuart J Pocock, Faiez Zannad, Milton Packer, Stefan D Anker
Empagliflozin, Health Status, and Quality of Life in Patients with Heart Failure and Preserved Ejection Fraction: The EMPEROR-Preserved Trial. Circulation (2021)
William T Cefalu, Sanjay Kaul, Hertzel C Gerstein, Rury R Holman, Bernard Zinman, Jay S Skyler, Jennifer B Green, John B Buse, Catherine M Viscoli, Lawrence A Leiter, Itamar Raz, Julio Rosenstock, Matthew C Riddle
Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a Diabetes Care Editors' Expert Forum. Diabetes care 41 (1) (2018)
Sanjay Kaul
Response to Comment on Kaul. Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes Care 2017;40:821-831. Diabetes care 40 (12) (2018)
Sanjay Kaul
Mitigating Cardiovascular Risk in Type 2 Diabetes With Antidiabetes Drugs: A Review of Principal Cardiovascular Outcome Results of EMPA-REG OUTCOME, LEADER, and SUSTAIN-6 Trials. Diabetes care 40 (7) (2017)